Aug 20, 2026 8:30am EDT FibroBiologics Announces Australian Patent Accepted for Cannabidiol Adjuvant Therapy for the Treatment of Degenerative Disc Disease
Aug 18, 2026 8:30am EDT FibroBiologics Announces Chondrocyte Spheroids Demonstrate Cartilage Repair in Preclinical Study of Degenerative Joints
Aug 11, 2026 8:30am EDT FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets
Aug 05, 2026 8:30am EDT FibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage
Jul 31, 2026 5:34pm EDT FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate
Jul 07, 2026 8:30am EDT FibroBiologics Completes Manufacturing of Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
Jun 30, 2026 8:30am EDT FibroBiologics to Participate in Fireside Chat at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Jun 29, 2026 4:01pm EDT FibroBiologics Announces Closing of up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Jun 26, 2026 8:30am EDT FibroBiologics Announces up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules